LONDON, February 27, 2015 /PRNewswire/ --
Report Details
Translational Regenerative Medicine - new study showing you trends, R&D progress, and predicted revenues
Where is the market for regenerative medicine heading? What are the commercial prospects for this market and related technologies? Visiongain's brand new report shows you potential revenues and other trends to 2025, discussing data, opportunities and prospects.
Visiongain's report lets you assess regenerative medicine: cell-based therapies that aim to restore function and regenerate diseased tissues. Our 260 page report provides 145 tables, charts, and graphs. Discover the most lucrative areas in the industry and the future market prospects. Our new study lets you assess forecasted sales at world market, submarket and national level. You will see financial results, interviews, trends, opportunities and revenue predictions.
Forecasts from 2015-2025 and other analyses show you commercial prospects
Besides revenue forecasting to 2025, our new study provides you with recent results, growth rates, and market shares. There you will find original analyses, with business outlooks and developments. Discover qualitative analyses (including SWOT and Porter's Five Forces), company profiles and commercial developments. Read the full transcript of an exclusive expert opinion interview from industry specialists informing your understanding and allowing you to assess prospects for investments and sales:
• Dr Antonio SJ Lee, CEO and Managing Director, MEDIPOST America Inc.
You find prospects for key submarkets and products
In addition to analyses of the overall world market, you see revenue forecasts for these three submarkets to 2025:
• Stem cell therapies
• Gene Therapies
• Tissue engineering products
Products that can significantly increase disease-free survival and improve patient tolerance will achieve success. In the long term, we forecast these curative therapies to be adopted by many healthcare systems globally.
Our investigation shows business research and analyses with individual revenue forecasts and discussions. You find dynamics of the industry and assess its potential sales, seeing agents likely to achieve the most success.
To see a report overview please email Sara Peerun on sara.peerun@visiongainglobal.com
See revenue forecasts for products
How will leading products perform to 2025 at the world level? Our study forecasts sales of currently marketed and pipeline regenerative medicine products including these:
• Osteocel Plus
• Trinity ELITE and Trinity Evolution
• Prochymal
• Apligraf
• Dermagraft
• ReCell
• Neovasculgen
• Glybera
• Talimogene Laherparepvec (T-Vec)
Discover how high revenues can go. You will see what is happening, understanding trends, challenges and opportunities.
What are the prospects for the leading regions and countries?
In addition to analyses of the overall world market, you discover individual revenue forecasts for regional markets to 2025, with discussions of countries. There are many commercial opportunities in developed and developing countries.
• US
• Europe
• Asia Pacific - including China, Japan, India, South Korea and Australia
• Rest of the world - including Brazil
Our analyses show sustained growth in the translational regenerative medicine market, particularly in Asia-Pacific where less regulatory pressures will catalyse successful market entry.
Leading companies and potential for market growth
This decade, this biotechnology sector will flourish - already there are products on sale and a myriad of clinical trials underway.
The R&D pipeline is strong and promising. Visiongain expects high demand for treatments, with degenerative diseases, wound healing, and other applications stimulating progress.
Our work shows you what products and organisations hold greatest potential. See profiles of 17 leading companies, including these:
• Alphatec Spine
• Anterogen
• Avita Medical
• Medipost
• Mesoblast
• NuVasive
• Organogenesis
• Osiris Therapeutics
• Regenerys
• TiGenix
• UniQure
A company profile gives you the following information
• Discussion of a company's activities and outlook, including product portfolio
• Recent financial results
• Assessment of recent developments - mergers and acquisitions (M&A), new products, and collaborations.
• Analysis of current clinical trial activity
• Insight into pipeline products in development
Discover capabilities, progress, and commercial prospects, helping you stay ahead. What effects will improved regulatory processes have? Advances in stem cell science and an evolving patent landscape will change the industry.
Research and development activities
What is happening in the R&D pipeline for translational regenerative medicine? You see developmental trends, gaining insight into the regenerative medicine R&D pipeline for:
• Cancer therapy
• Cardiovascular and cardiology treatments
• Diabetes treatments
• Ocular (ophthalmological) uses - treating eye diseases
• Treatments for neurological disorders
• Wound care
What issues will affect the translational regenerative medicine market?
Our new report lets you assess industry trends and outlooks. Our study discusses issues affecting regenerative medicine. You will find discussions, including qualitative analyses:
• Tissue engineering - including 3D bioprinting and organ transplants
• Autologous chondrocyte implantation (ACI)
• Haematopoietic stem cell transplantation and other cellular treatments
• Orthobiologics, biomaterials, neuroprotection and nanotechnology
• Gene therapy, including delivery and viral vectors
• Bone marrow material and human embryonic stem cells
• Mesenchymal stem cell technologies
• Skin regeneration, wound repair, cosmetic uses and treating degenerative disorders
• Treatment of leg ulcers, cartilage, livers, hearts and eyes
You will see discussions of technological, commercial, and economic matters, with emphasis on organisations developing technologies.
To see a report overview please email Sara Peerun on sara.peerun@visiongainglobal.com
How theTranslational Regenerative Medicine: Market Prospects 2015-2025 report helps you
In summary our new 261 page report gives you the following knowledge:
• Revenues to 2025 for the overall regenerative medicine market and 3 submarkets - discover the industry's prospects, finding promising technology areas for investments and revenues
• Assessment of the products within the regenerative medicine market - discover prospects for leading products with forecasted revenues provided to 2025
• Revenue forecast to 2025 for leading regional markets - US, Europe, Asia-Pacific and Rest of the World
• Evaluation of pipeline drugs - find the market potential for leading products currently in the development pipeline in each market segment and for various therapeutic areas
• Assess leading companies - hear about products, results and strategies, including recent activities and outlook for 17 leading companies such as Organogenesis, Osiris Therapeutics, NuVasive and UniQure
• Discussion of what stimulates and restrains companies and the market
• Prospects for established firms and those seeking to enter the market
• Opinions from our survey, seeing interviews with industry authorities
You will find quantitative and qualitative analyses with independent predictions. You receive information that only our report contains, staying informed with this invaluable business intelligence.
Information found nowhere else
With our survey you are less likely to fall behind in knowledge or miss opportunities. See how you could benefit your research, analyses, and decisions. Also see how you can save time and receive recognition for commercial insight.
Visiongain's study is for everybody needing commercial analyses for the regenerative medicine market. You will find data, trends and predictions. Please order our report now.
To request an exec summary of this report please email Sara Peerun at sara.peerun@visiongainglobal.com or call Tel: +44(0)20-7336-6100
Or click on https://www.visiongain.com/Report/1390/Translational-Regenerative-Medicine-Market-Prospects-2015-2025
Companies Listed In this Report
Aastrom Biosciences
Advanced BioHealing
Advanced Cell Technology
Advanced Tissue Sciences
Advantagene
AlloSource
AlphaTec Spine
Amedica
Amgen
Amorcyte
Amorepacific Group
AnGes MG
Angioblast Systems
Anika Therapeutics
Anterogen
Arcarios B.V
Ark Therapeutics
Athersys Inc
Avita Medical
AxoGen
Baxter
Beike Biotechnology
Benda Pharmaceutical
BioD
Bioheart
BioMed Realty Trust, Inc
BioSante Pharmaceuticals
BioTime
BioTissue AG
BioVex Inc
Blackstone Medical
BrainStorm Cell Therapeutics
California Stem Cell Inc
Capricor
Cardio3BioSciences
Celgene
Cell Targeting
CellCo Tec
Cellerant Therapeutics
Cephalon
Ceregene
CHA Biotech
Chiesi Farmaceutici
Cipla
Co.don AG
Cold Genesys
Cook Biotech Inc
Cytomedix
Cytori Therapeutics
Daiichi Sankyo
DePuy Mitek (Johnson & Johnson)
FibroCell
Gamida Cell Ltd
Genzyme Corporation (Sanofi)
Histogenics
Humacyte
Human Stem Cell Institute
Insulete Inc
Interxon Corporation
ISTO Technologies
Janssen Biotech Inc
Japan Tissue Engineering Co
JCR Pharmaceuticals
Johnson & Johnson
Kinetic Concept Inc
LecTec Corporation
Lincoln Park Capital
Lonza
MacroCure
Medipost
Medtronic
Mesoblast
Mitsubishi Tanabe
Myriad Genetics
Neostem
Neuralstem
Nippon Zoki Pharmaceuticals
NuVasive
Ocata Therapeutics
OncoCyte
Organovo
Orphan Biovitrum AB (Sobi)
Orthofix
Osiris Therapeutics
Oxford BioMedica
Parcell Laboratories
Pfizer
Pharmicell
Regenerys
Reliance Life Sciences
ReNeuron
RTI Surgical
Rusnano Corporation
Sangamo Biosciences
Sanofi
Shanghai Sunway Biotech
Shenzhen Sibiono GeneTech
Shire
Singapore General Hospital
Skye Orthobiologics
Smith & Nephew
Sobi Partners
Spark Therapeutics
StemCells
Stempeutics Research
Stratatech Corporation
TCA Cellular Therapy
Tengion Inc
Teva Pharmaceuticals
TiGenix
UniQure
Viacyte Inc
Vital Therapies
WKD Holding Oy
Xcellerex
Xenetic Biosciences
Zimmer
Organisations Mentioned In The Report
Arthritis Research UK
Associazione Infermieristica per lo Studio delle Lesioni Cutanee (AISLeC) [China]
Australian Regenerative Medicine Institute
Australian Sports Anti-Doping Authority (ASADA)
Biomedical Advanced Research and Development Authority (BARDA)
British Heart Foundation [UK]
California Institute of Regenerative Medicine (CIRM)
Cambridge Stem Cell Biology Institute [UK]
Case Western Reserve University
Catalan Institution for Research and Advanced Studies
Center for Biologics Evaluation and Research (CBER) [US]
CHA General Hospital [Korea]
Cryocenter Saint Petersburg
Drugs Controller General of India (DCGI)
European Group for Blood and Marrow Transplantation (EBMT)
European Medicines Agency
Food and Drugs Agency (FDA) [US]
Haute Autorité de santé [France]
Heriot-Watt University
Human Fertilisation and Embryology Authority (HFEA)
Institute of Biomedical Research and Innovation Hospital [Japan]
International Society for Stem Cell Research (ISSCR)
Karolinska Institute [Sweden]
Massachusetts General Hospital (MGH)
Mayo Clinic [US]
Medical Research Council [UK]
Ministry of Food and Drug Safety, MFDS) [Korea]
Ministry of Health, Labour and Welfare (MHLW) [Japan]
Ministry of Science and Technology [China]
Moorfields Eye Hospital
National Tissue Engineering Center (NTEC) [China]
New York Blood Center
Riken Center for Developmental Biology
RUSH University Medical Center [US]
Russian Ministry of Healthcare and Social Development
Saudi Food and Drug Authority [Saudi Arabia]
Scottish Centre for Regenerative Medicine
Sotex Pharm Firm LLC
St. Jude's Children Research Hospital
State Food and Drug Administration (SFDA) [China]
SUNY Upstate Medical University
The Genetico Center [Russia]
The StemGen Organisation
Therapeutics Goods Administration (TGA) [Australia]
UH San Diego Sanford Stem Cell Clinical Center
UK Medicines and Healthcare Products Regulatory Agency (MHRA)
Universitat Autònoma de Barcelona [Spain]
University College London
University of Edinburgh MRC Centre for Regenerative Medicine [UK]
University of Massachusetts (UMass) Memorial Hospital
University of Modena Centre for Regenerative Medicine [Italy]
University of Wisconsin
Wake Forest Institute
Weizmann Institute of Science [Israel]
Wellcome Trust
World Health Organization
Yale School of Medicine
To see a report overview please email Sara Peerun on sara.peerun@visiongainglobal.com or call Tel: +44(0)20-7336-6100
SOURCE Visiongain
